SWISS pharmaceutical giant Novartis has announced Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention.
The study showed 50% of patients taking erenumab 140mg had their migraine days cut by at least half, nearly three-fold higher odds compared to placebo, the company said - visit novartis.gcs-web.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Dec 17
